Equities research analysts expect Zoetis Inc (NYSE:ZTS) to report sales of $1.41 billion for the current quarter, Zacks reports. Five analysts have made estimates for Zoetis’ earnings. The lowest sales estimate is $1.39 billion and the highest is $1.42 billion. Zoetis reported sales of $1.28 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.2%. The business is expected to issue its next earnings results before the market opens on Thursday, February 15th.
According to Zacks, analysts expect that Zoetis will report full-year sales of $1.41 billion for the current year, with estimates ranging from $5.24 billion to $5.27 billion. For the next fiscal year, analysts forecast that the company will report sales of $5.63 billion per share, with estimates ranging from $5.57 billion to $5.69 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Zoetis.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the firm earned $0.52 earnings per share. Zoetis’s revenue was up 8.5% on a year-over-year basis.
A number of institutional investors and hedge funds have recently modified their holdings of ZTS. Dynamic Technology Lab Private Ltd lifted its position in Zoetis by 7.3% in the second quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after purchasing an additional 401 shares during the last quarter. Balyasny Asset Management LLC lifted its position in Zoetis by 55.5% in the second quarter. Balyasny Asset Management LLC now owns 44,330 shares of the company’s stock valued at $2,765,000 after purchasing an additional 15,830 shares during the last quarter. Quantbot Technologies LP bought a new stake in Zoetis in the third quarter valued at approximately $3,972,000. Prudential PLC lifted its position in Zoetis by 4.8% in the second quarter. Prudential PLC now owns 149,389 shares of the company’s stock valued at $9,319,000 after purchasing an additional 6,811 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its position in Zoetis by 51.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 31,041 shares of the company’s stock valued at $1,936,000 after purchasing an additional 10,539 shares during the last quarter. 93.14% of the stock is owned by institutional investors and hedge funds.
Zoetis (NYSE ZTS) opened at $75.54 on Wednesday. Zoetis has a twelve month low of $52.00 and a twelve month high of $76.40. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $36,810.00, a PE ratio of 39.76, a PEG ratio of 1.90 and a beta of 1.06.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be paid a $0.126 dividend. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $0.50 annualized dividend and a yield of 0.67%. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio is currently 22.11%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.